Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928030 · ClinicalTrials.gov registry record · Phase 1
Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01928030: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01928030 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01928030, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in patients with lymphedema.
Interventions
- BIOLOGICAL recombinant human hyaluronidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928030
The ClinicalTrials.gov registry entry for NCT01928030 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant human hyaluronidase is the first listed.
NCT01928030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01928030 about?
NCT01928030 is a clinical study titled "Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer". This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer. Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in patients with lymphedema.
What is the current status of trial NCT01928030?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2013-12. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01928030?
The interventions under investigation include: recombinant human hyaluronidase (BIOLOGICAL).
Who is sponsoring clinical trial NCT01928030?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.